Hou Yanjun, Tozbikian Gary, Zynger Debra L, Li Zaibo
From the Department of Pathology, The Ohio State University Wexner Medical Center, Columbus.
Am J Clin Pathol. 2017 Jun 1;147(6):541-548. doi: 10.1093/ajcp/aqx008.
This study aimed to compare a modified Magee equation with Oncotype DX (Genomic Health, Redwood City, CA) recurrence score (RS) and identify patients who are unlikely to benefit from Oncotype DX.
Magee equation RS was calculated in 438 cases and correlated with Oncotype DX RS.
The Pearson correlation coefficient ( r ) for the Magee equation and Oncotype DX RS was 0.6645 ( P < .00001), and the overall agreement was 66.4%. All cases (11.6%) with a Magee equation RS greater than 30 or 11 or less had been correctly predicted to have either high Oncotype DX RS or low Oncotype DX RS, respectively.
The modified Magee equation is able to identify up to 12% patients who are unlikely to benefit from Oncotype DX testing. Using the modified Magee equation RS on these patients would be an alternative to Oncotype DX, leading to cost savings.
本研究旨在比较改良的马吉方程与Oncotype DX（基因组健康公司，加利福尼亚州红木城）复发评分（RS），并识别不太可能从Oncotype DX中获益的患者。
计算了438例患者的马吉方程RS，并将其与Oncotype DX RS进行关联。
马吉方程与Oncotype DX RS的Pearson相关系数（r）为0.6645（P <.00001），总体一致性为66.4%。所有马吉方程RS大于30或小于或等于11的病例（11.6%）分别被正确预测为Oncotype DX RS高或低。
改良的马吉方程能够识别出多达12%不太可能从Oncotype DX检测中获益的患者。对这些患者使用改良的马吉方程RS将是Oncotype DX的替代方法，可节省成本。
